BioSpace News Archive

Shuttle Pharmaceuticals Holdings, Inc. (Nasdaq: SHPH) today announced it has engaged Theradex Oncology, a leading clinical research organization (“CRO”), to help prepare for its upcoming clinical study of Ropidoxuridine.

Blueprint Medicines Corporation (NASDAQ: BPMC) today announced the acceptance of abstracts highlighting long-term clinical outcomes and impact on overall survival of AYVAKIT® (avapritinib) in patients with advanced systemic mastocytosis (SM), as well as real-world evidence characterizing the burden of SM, for presentation at the 2022 American Society of Hematology (ASH) Annual Meeting in December.

I-Mab (the “Company”) (Nasdaq: IMAB), a clinical-stage biopharmaceutical company committed to the discovery, development, and commercialization of novel biologics, today announced that two poster presentations featuring preclinical and translational research data of lemzoparlimab, will be presented at the 64th American Society of Hematology (ASH) Annual Meeting, taking place December 10-13, 2022, in New Orleans, Louisiana.

CenTrak unveils the expansion of TruView’s wander management capabilities to include unique roaming alert features and announces the platform’s emergency call system has met the rigorous safety standards and testing required by the UL 2560 certification process.

Orum Therapeutics, a private biotechnology company pioneering the development of tumor-directed targeted protein degraders (TPDs), today announced the presentation of preclinical data for ORM-6151, a first-in-class, anti-CD33 antibody-enabled GSPT1 degrader for acute myeloid leukemia (AML).

Arima Genomics, Inc., the leader in 3D genomics, today announced a new partnership with Basepair to empower scientists with new options for bioinformatic analysis of 3D genomic data.

Aptose Biosciences Inc. announced that clinical data for tuspetinib, a myeloid kinome inhibitor, and luxeptinib, a dual lymphoid and myeloid inhibitor, have been accepted for poster presentations at the 64th American Society of Hematology Annual Meeting and Exposition, being held Saturday, December 10 – Monday, December 13, 2022 in New Orleans, LA and virtually.

OraSure Technologies, Inc. (NASDAQ: OSUR), a global leader in point-of-care and home diagnostic testing and sample collection technologies, announced today that the Company received U.S. FDA clearance for its ORAcollect®•Dx saliva collection device for OTC (i.e. direct-to-consumer) use.

Harpoon Therapeutics, Inc. announced that it will present updated interim data from its Phase 1 clinical trial evaluating single-agent HPN217 in relapsed/refractory multiple myeloma in a poster presentation at the 64th American Society of Hematology Annual Meeting and Exposition being held in person in New Orleans, Louisiana and virtually from December 10-13, 2022.

Omeros Corporation announced that two presentations pertaining to Omeros’ investigational complement inhibitors will be featured at the upcoming 64th American Society of Hematology Annual Meeting, which will be held from December 10-13, 2022 in New Orleans.